The genomic imprint of cancer therapies helps timing the formation of metastases
暂无分享,去创建一个
Z. Szallasi | I. Csabai | L. Reiniger | O. Pipek | T. Glasz | J. Moldvay | D. Ribli | M. Krzystanek | D. Szüts | E. Németh | Z. Sztupinszki
[1] Mi Ni Huang,et al. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors , 2017, bioRxiv.
[2] A. Drilon,et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes , 2018, Nature Reviews Clinical Oncology.
[3] E. Fearon,et al. Lymph Node Metastases in Colon Cancer Are Polyclonal , 2017, Clinical Cancer Research.
[4] Maximilian Diehn,et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.
[5] Yossi Farjoun,et al. Characterization and remediation of sample index swaps by non-redundant dual indexing on massively parallel sequencing platforms , 2017, BMC Genomics.
[6] K. Akashi,et al. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. , 2017, Lung cancer.
[7] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[8] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[9] A. Schäffer,et al. The evolution of tumour phylogenetics: principles and practice , 2017, Nature Reviews Genetics.
[10] Anthony T Papenfuss,et al. Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia , 2017, Nature Communications.
[11] M. Ohba,et al. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation , 2017, Molecular Cancer Research.
[12] Quan Li,et al. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.
[13] Christopher A. Miller,et al. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases , 2016, PLoS medicine.
[14] Christopher A. Miller,et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers , 2016, Nature Communications.
[15] Joshua F. McMichael,et al. Visualizing tumor evolution with the fishplot package for R , 2016, bioRxiv.
[16] Gábor E. Tusnády,et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.
[17] M. Stratton,et al. Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.
[18] Charles Swanton,et al. Metastasis as an evolutionary process , 2016, Science.
[19] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[20] Y. Li,et al. EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer , 2016, Oncology letters.
[21] James E. Verdone,et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters , 2016, Proceedings of the National Academy of Sciences.
[22] Obi L. Griffith,et al. Optimizing cancer genome sequencing and analysis. , 2015, Cell systems.
[23] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[24] Andrew Menzies,et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.
[25] R. Jain,et al. Using tumour phylogenetics to identify the roots of metastasis in humans , 2015, Nature Reviews Clinical Oncology.
[26] G. Getz,et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.
[27] M. Nykter,et al. The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.
[28] Z. Szallasi,et al. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Andrew Menzies,et al. Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.
[30] J. Blangero,et al. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility , 2014, Endocrine-related cancer.
[31] Shankar Vembu,et al. PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors , 2015, Genome Biology.
[32] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.
[33] Roland Eils,et al. circlize implements and enhances circular visualization in R , 2014, Bioinform..
[34] Charles Swanton,et al. Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.
[35] Serena Nik-Zainal,et al. Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.
[36] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.
[37] Obi L. Griffith,et al. SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution , 2014, PLoS Comput. Biol..
[38] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[39] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[40] Mari Mino-Kenudson,et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.
[41] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[42] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[43] David C. Jones,et al. Signatures of mutational processes in human cancer this access benefits you. Your matters , 2013 .
[44] Michael C. Rusch,et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.
[45] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[46] P. Jänne,et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor , 2010, Oncogene.
[47] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[48] Y. Yatabe,et al. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. , 2008, Cancer research.
[49] J. Osinga,et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. , 2005, Cancer research.
[50] S. Scully,et al. The human homolog of yeast SEP1 is a novel candidate tumor suppressor gene in osteogenic sarcoma. , 2002, Gene.